Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Rockwell Medical (RMTI) over the last 17 years, with Sep 2025 value amounting to $229,000.

  • Rockwell Medical's Capital Expenditures rose 19.90% to $229,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $851,000, marking a year-over-year increase of 29.14%. This contributed to the annual value of $1.0 million for FY2024, which is 255.99% up from last year.
  • According to the latest figures from Q3 2025, Rockwell Medical's Capital Expenditures is $229,000, which was up 39.63% from $164,000 recorded in Q2 2025.
  • In the past 5 years, Rockwell Medical's Capital Expenditures registered a high of $395,000 during Q4 2024, and its lowest value of -$80,000 during Q3 2022.
  • For the 3-year period, Rockwell Medical's Capital Expenditures averaged around $159,182, with its median value being $145,000 (2023).
  • As far as peak fluctuations go, Rockwell Medical's Capital Expenditures plummeted by 162.99% in 2022, and later spiked by 1,093.75% in 2024.
  • Rockwell Medical's Capital Expenditures (Quarterly) stood at $114,000 in 2021, then spiked by 146.49% to $281,000 in 2022, then plummeted by 84.70% to $43,000 in 2023, then soared by 818.60% to $395,000 in 2024, then increased by 19.90% to $229,000 in 2025.
  • Its Capital Expenditures stands at $229,000 for Q3 2025, versus $164,000 for Q2 2025 and $63,000 for Q1 2025.